The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatitis B Surface Antibody Titers and Hepatitis B Reactivation with Direct-Acting Antiviral Therapy for Hepatitis C
J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13421. Online ahead of print.
Shiva Poola1, Sirish Sanaka1, Kerry Sewell2, Hans L Tillmann1345
Author information
1East Carolina University, Department of Medicine, Greenville, NC, 27834, USA.
2East Carolina University, Research Librarian for the Health Sciences, Greenville, NC, 27834, USA.
3East Carolina University, Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Greenville, NC, 27834, USA.
4Vidant Medical Center, Moye Blvd, Greenville, NC, 27834, USA.
5Greenville VA Health Care Center, 401 Moye Blvd, Greenville, NC, 27834, USA.
Abstract
HBV reactivation can occur while undergoing direct active antiviral (DAA) therapy for hepatitis C virus (HCV). The role of hepatitis B surface antibody (HBsAb) has not been systematically explored. Therefore, the purpose of this systematic review explores the role of the presence of HBsAb on the risk of HBV reactivation. We reviewed Medline, CINAHL, EMBASE, and Cochrane Central for studies on DAA therapy and data on HBsAb in patients with resolved hepatitis B (hepatitis B surface antigen-negative and hepatitis B core antibody-positive). We identified twenty-nine reports: thirteen case reports with HBV reactivation (10 HBsAb negative and 3 HBsAb positive patients) and sixteen cohort studies totaling 2528 patients with resolve HBV infection (1429 HBsAb negative, 1099 HBsAb positive). Reactivation was found in 12 (0.8%) HBsAb negative and 7 (0.6%) HBsAb positive of cohort studies. All but two HBV reactivation occurred in patients with HBsAb titer < 30 iU/L. Presence of HBsAb showed a trend towards delayed reactivation (median 12 weeks vs. 9.5 weeks; p= 0.07). Importantly, with the exception of a patient with escape variant and an HIV infected individual, no HBsAb positive individual demonstrated clinical reactivation. HBsAb presence seems to protect from clinical HBV reactivation related to DAA therapy. The most pronounced prevention for reactivation may require titers greater than 30 iU/L.